Trends in HIV Care

Trends in HIV Care in Sub-Saharan Africa

2010 WHO Treatment Guidelines: CD4 <350 cells/µL

2013 WHO Treatment Guidelines: CD4 <500 cells/µL

2015 WHO Treatment Guidelines: Treat All

Data not displayed for some years because of small cell sizes.
Data not displayed for some years because of small cell sizes.
Many patients enrolling in HIV care after 2015 are excluded because of insufficient potential follow-up time before database close.
Many patients initiating ART after 2015 are excluded because of insufficient potential follow-up time before database close.
Patients enrolling in HIV care in 2017 are not shown because of insufficient potential follow-up time before database close.
Patients initiating ART in 2017 are not shown because of insufficient potential follow-up time before database close.
IeDEA sites in Ghana serve pediatric patients only.
IeDEA sites in Mali serve pediatric patients only.

Notes:

Regional and country level aggregate data are generated from regional patient-level databases, using the IeDEA Data Exchange Standard (DES). Data reflects the situation at clinics contributing data to IeDEA, which may not be nationally representative.
All ART-naïve patients newly enrolling in HIV care from 2010 to present at a site participating in IeDEA were eligible for inclusion if they had at least 15 months between enrollment and database close or transfer to another site of care. The following patients were excluded: patients with incomplete data related to age, sex, and site of enrollment and patients with evidence of ART initiation prior to the date of enrollment.

Definitions:

Enrollment in HIV care: Enrollment in HIV care at a site participating in the IeDEA consortium, based on the date of enrollment recorded in the database.
Timely ART initiation: Initiation of a combined regimen of antiretroviral medications within 7 days, 14 days, 30 days, and 12 months after enrollment at a site participating in IeDEA.
Viral load monitoring: Any record of a viral load test at 6 months (+/- 3 months) and 12 months (+/- 3 months) after treatment initiation.
Viral suppression: Viral load <1,000 copies/mL among patients with a recorded viral load test at 6 months (+/- 3 months) and 12 months (+/- 3 months) after the date of treatment initiation at a site participating in IeDEA. Patients with no viral load test result within the ascertainment windows are excluded from viral suppression measures. For patients with >1 viral load test result within the ascertainment window, the lowest recorded viral load measure was used.

Visit the Measures and Methodology page for information about data methods, sources, definitions, and suppression rules.

Notes:

No data suppression rules are applied to the clinic and country-level data that are accessible through password-protected clinic user accounts. Caution is advised when interpreting data visualizations and trends for small numbers of patients.
Country-level data are aggregated from patient-level databases at clinics participating in IeDEA, using the IeDEA Data Exchange Standard (DES). These clinics are not nationally representative. Aggregated country-level data that are accessed through password-protected clinic user accounts may differ from data displayed on the public version of the Treat All Dashboard because of differences in exclusion criteria and suppression rules.
All ART-naïve patients newly enrolling in HIV care since 2010 at clinics that participate in IeDEA were eligible for inclusion. The following patients were excluded: patients with incomplete data related to age, sex, and site of enrollment and patients with evidence of ART initiation prior to the date of enrollment.

Definitions:

Enrollment in HIV care: Enrollment in HIV care at a site participating in the IeDEA consortium, based on the date of enrollment recorded in the database. All patients enrolling in HIV care are included, irrespective of follow-up time and ART initiation status.
Timely ART initiation: Initiation of a combined regimen of antiretroviral medications within 7 days, 14 days, 30 days, and 12 months after enrollment at a site participating in IeDEA among ART-naive patients.
Viral load monitoring: Any record of a viral load test at 6 months (+/- 3 months) and 12 months (+/- 3 months) after treatment initiation.
Viral suppression: Viral load <1,000 copies/mL among patients with a recorded viral load test at 6 months (+/- 3 months) and 12 months (+/- 3 months) after the date of treatment initiation at a site participating in IeDEA. Patients with no viral load test result within the ascertainment windows are excluded from viral suppression measures. For patients with >1 viral load test result within the ascertainment window, the lowest recorded viral load measure was used.

Visit the Measures and Methodology page for information about data methods, sources, definitions, and suppression rules.